GenoMed Seeks to Avoid Physicians' Malpractice Exposure over West Nile Virus
CONTACT: GenoMed Inc. David W. Moskowitz, MD, MA, FACP (314) 983-9933 dwmoskowitz@genomedics.com
ST. LOUIS, MO. – August 13, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that it has begun alerting State Medical Societies to its article on treating West Nile virus encephalitis for the good of their physician members and their members' patients. GenoMed has been forced to do this given the failure of federal, state, county, and city public health authorities to publicize the Company's new treatment.
Said Dr. David W. Moskowitz, GenoMed's Chairman and CEO, "We recently published an article describing a simple, safe, effective treatment for West Nile virus encephalitis in a peer-reviewed medical journal. Since there are 70,000 medical journals, I know how hard it is to keep up with the literature. It's especially hard when an article isn't highlighted by the media or the public health authorities who mention West Nile virus every day, it seems. But family members of WNV victims have every right to expect physicians to know the medical literature. It's a professional obligation we take on ourselves."
Dr. Moskowitz says in his emails to the State Medical Societies, "Any help in making your members aware of our article would be most appreciated. Whether they choose to use our method is, of course, their decision, and why they have been granted a medical license to use their best judgment. But I think you'll agree that from the medico-legal point of view they should at least be aware of our article."
Dr. Moskowitz added, "I'm disappointed that the public health establishment hasn't done its job, at least in terms of how it went about eradicating polio in the 1950's. Public health authorities nowadays say with pride that they are forbidden from endorsing any particular clinical treatment or trial. This was certainly not their forbears' attitude in the 1950s."
Dr. Moskowitz concluded, "But public health figures have sovereign immunity, and can't be sued. Not so the poor physician. Inaction by the public health establishment doesn't absolve the individual physician from his/her responsibility to keep up with the literature. As often happens, the physician winds up holding the bag for systemic failures by others."
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is a Next Generation DMTM (Disease Management) company whose mission is to improve clinical outcomes by identifying the genetic pathways that cause disease. GenoMed is currently marketing its protocol for delaying complications like kidney failure due to high blood pressure and diabetes. Eighty million Americans are at increased risk for kidney failure. GenoMed is also marketing its method for delaying emphysema, which 3 million Americans have, and another 60 million smokers are at increased risk of getting.
This summer GenoMed is coordinating nation-wide treatment for West Nile virus using the Company's patent-pending protocol, which exploits already existing, FDA-approved drugs. Anyone can enroll simply by clicking on the "West Nile trial" link at genomed.com.
. |
